Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool for Cancer, Advanced
Phase-Based Progress Estimates
Effectiveness
Safety
San Francisco Veterans Medical Center, San Francisco, CA
Cancer, Advanced
Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool - OtherEligibility
65+
All Sexes
What conditions do you have?
Select
Eligibility
65+
All Sexes
What conditions do you have?
Select
Study Summary
This is a minimal risk, pilot cluster randomized controlled trial (CRT) to determine the feasibility and acceptability of training medical oncologists to use the Best Case/Worst Case-Geriatric Oncology (BC/WC-GeriOnc) communication tool in clinical practice with older adults with advanced cancer.
Treatment Effectiveness
Effectiveness Progress
Other trials for Cancer, Advanced
Study Objectives
5 Primary · 5 Secondary · Reporting Duration: Completed once at the end of study participation (approximately 18 months)
1 day
Enrollment rate
3 months
Retention rate
Month 18
Practitioner Opinion Survey (Lead-In and BC/WC-GeriOnc Intervention Groups Only)
Qualitative oncologist-reported feasibility (Lead-In and BC/WC-GeriOnc Intervention Groups Only)
Week 2
Acceptability of Intervention Measure (Lead-In and BC/WC-GeriOnc Intervention Groups Only)
BC/WC-GeriOnc Intervention Adherence (Lead-In and BC/WC-GeriOnc Intervention Groups Only)
BC/WC-GeriOnc Intervention Fidelity (Lead-In and BC/WC-GeriOnc Intervention Groups Only)
Duration of audio-recorded decision-making discussions
Feasibility of Intervention Measure (Lead-In and BC/WC-GeriOnc Intervention Groups Only)
Intervention Appropriateness Measure (Lead-In and BC/WC-GeriOnc Intervention Groups Only)
Trial Safety
Safety Progress
Other trials for Cancer, Advanced
Trial Design
3 Treatment Groups
Waitlist Control
1 of 3
Lead-In (BC/WC-GeriOnc)
1 of 3
Intervention (BC/WC-GeriOnc)
1 of 3
Active Control
Experimental Treatment
96 Total Participants · 3 Treatment Groups
Primary Treatment: Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool · No Placebo Group · N/A
Lead-In (BC/WC-GeriOnc)
Other
Experimental Group · 1 Intervention: Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool · Intervention Types: OtherIntervention (BC/WC-GeriOnc)
Other
Experimental Group · 1 Intervention: Best Case/Worst Case (BC/WC) Geriatric Oncology (GeriOnc) communication tool · Intervention Types: OtherWaitlist ControlNoIntervention Group · 1 Intervention: Waitlist Control · Intervention Types:
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: completed once at the end of study participation (approximately 18 months)
Closest Location: San Francisco Veterans Medical Center · San Francisco, CA
2016First Recorded Clinical Trial
1 TrialsResearching Cancer, Advanced
1 CompletedClinical Trials
Who is running the clinical trial?
National Institute on Aging (NIA)NIH
1,348 Previous Clinical Trials
3,261,801 Total Patients Enrolled
1 Trials studying Cancer, Advanced
80 Patients Enrolled for Cancer, Advanced
University of California, San FranciscoLead Sponsor
2,246 Previous Clinical Trials
11,473,578 Total Patients Enrolled
1 Trials studying Cancer, Advanced
6,400 Patients Enrolled for Cancer, Advanced
Melisa L Wong, MD, MASPrincipal InvestigatorUniversity of California, San Francisco
Eligibility Criteria
Age 65+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a solid tumor malignancy that is currently in the stage IV (per AJCC 8th Edition) or stage III (per AJCC 7th Edition) and has not been treated with curative intent.
You are a physician who has completed an oncology fellowship and is independently practicing.
You are a current or former faculty member of the Helen Diller Family Comprehensive Cancer Center (HDFCCC) affiliated site.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments